Background: Leukocyte activation results in a rapid increase in adhesion to the extracellular matrix due to the activation of β1 integrin receptors. A role for phosphatidylinositol (PI) 3-kinase in integrin activation has been proposed, as activation of integrins by many receptors can be blocked by PI 3-kinase inhibitors. One receptor that regulates integrins is the CD28 surface antigen; here, we investigated the mechanisms responsible for CD28-mediated integrin activation.
Background
Activation of leukocytes can result in rapid changes in the functional activity of adhesion receptors expressed on the cell surface [1] . Although resting T lymphocytes express integrins such as α4β1, α5β1, and αLβ2 on their cell surface, these cells bind poorly to integrin extracellular matrix ligands and cellular counter-receptors for these ligands. However, activation of T lymphocytes results in a rapid increase in integrin-mediated adhesion which does not involve an increase in the cell surface expression of integrins [2] [3] [4] . This mode of adhesion regulation plays a critical role in the interaction between antigen-specific lymphocytes and antigen-presenting cells, the migration of lymphocytes through lymphoid tissue, and the multistep cascade that allows for leukocyte exit from the bloodstream via interactions with vascular endothelium [1, 5] .
Engagement of several different receptors on the T lymphocyte surface can generate intracellular signals that activate integrin-mediated adhesion. These receptors include the antigen-specific complex containing the T-cell receptor and the CD3 group of signaling proteins, T-cell coreceptors such as CD2 and CD7, and some serpentine G-protein-coupled chemokine receptors [2] [3] [4] 6, 7] . The focus of this report is on one such regulator of integrin activation, the CD28 surface antigen. CD28 stimulation is a critical component of T-cell signaling responses that lead to proliferation and cytokine production [8] . The cytoplasmic tail of CD28 contains a binding motif, Y 173 MNM (single-letter amino acid code), for proteins containing Src homology 2 (SH2) domains. CD28 engagement leads to phosphorylation of Tyr173 and the subsequent association of several SH2-domain-containing proteins with CD28, including the Grb2-Sos adaptor protein complex, and the p85 regulatory subunit of the lipid kinase phosphatidylinositol (PI) 3-kinase [9] [10] [11] . Genetic and pharmacological studies have suggested a role for CD28-mediated activation of PI 3-kinase in CD28 signaling in some, but not all, cell systems [11] [12] [13] [14] [15] [16] .
We have recently proposed that PI 3-kinase has a central role in the regulation of integrin-mediated adhesion by CD28 and other integrin regulators [17] . One mechanism by which these integrin regulators are coupled to PI-3-kinase-dependent pathways of integrin activation may involve the assembly of multiprotein intracellular complexes mediated by adaptor proteins upon cell stimulation. One such adaptor protein is p120 cbl (Cbl), a 120 kDa cytoplasmic protein that contains numerous tyrosine residues and proline-rich regions that could potentially interact with proteins containing SH2 and SH3 domains [18] . Rapid tyrosine phosphorylation of Cbl has been observed following stimulation of several cell surface receptors, including the T-cell receptor [19] , surface immunoglobulin [20] , the FcεRI receptor (for the constant region of immunoglobulin E) [21] , and the epidermal growth factor receptor [22] . Additionally, Cbl associates with many adaptor and/or signaling molecules, including Grb2 [20, 23, 24] , Nck [25] , Crk [24] , Shc [20] , p59 fyn [20, 23] , Syk [20] , p85 [20, 23, 26] , and 14-3-3 proteins [27] . A role for Cbl in regulation of the Ras pathway and the Syk tyrosine kinase has also been proposed [21, 28, 29] .
In this report, we demonstrate that CD28-mediated activation of β1 integrins requires PI 3-kinase, but does not require association of PI 3-kinase with the SH2-binding motif in the CD28 cytoplasmic domain. Rather, we find that this SH2-binding motif has a central role in CD28-mediated tyrosine phosphorylation of Cbl, which results in recruitment and activation of PI 3-kinase. As a mutant form of Cbl with reduced ability to bind to p85 can inhibit CD28-mediated integrin activation, we suggest that Cbl has a specific role in regulating cell adhesion.
Results and discussion CD28-mediated activation of b1 integrin function is dependent on PI 3-kinase An expression construct encoding a chimeric receptor consisting of the CD2 extracellular and transmembrane domains fused in-frame to the CD28 cytoplasmic domain (CD2/28) was expressed in the HL60 myelomonocytic cell line (Figure 1a) , which expresses the α4β1 and α5β1 integrins. This cell line exhibits activation-dependent adhesion to fibronectin, as demonstrated by the rapid increase in HL60 adhesion to fibronectin following stimulation with the phorbol ester phorbol myristate acetate (PMA) or direct activation of β1 integrins with the β1-integrin-specific monoclonal antibody TS2/16 ( Figure 1b) . Stimulation of CD2/28-expressing HL60 transfectants via cross-linking of the CD2/28 chimera with a CD2-specific monoclonal Research Paper Cbl and integrin-mediated cell adhesion Zell et al. 815
Figure 1
The Y173F mutation in the CD28 cytoplasmic tail inhibits β1 integrin activation, p85 recruitment and PI 3-kinase activation. (a) Flow cytometric analysis of HL60 transfectants expressing CD2/28, CD2/28Y173F, CD2/28Y188F, CD2/28Y191F and CD2/28Y200F. Expression of CD2/28 and β1 integrin was assessed by single-color flow cytometry as described [38] . Binding of a negative control monoclonal antibody is shown in the open profiles in each panel of the histograms. All transfectants also expressed comparable levels of α4 and α5 integrin (data not shown). (b) Adhesion of HL60 transfectants to fibronectin (FN; 1 µg per well) was assessed as previously described [13] after no stimulation, or stimulation for 10 min at 37°C with cross-linking using the negative control monoclonal antibody 10F7, cross-linking of CD2/28 with the CD2-specific monoclonal antibody TS2/18 or 10 ng/ml PMA. (c) The Y173F mutation inhibits CD2/28-mediated recruitment of p85. Cells were either left unstimulated or were stimulated for 5 min with the CD2-specific monoclonal antibody TS2/18, and the CD2/28 receptor was immunoprecipitated from cell lysates and subjected to SDS-PAGE. Western blots were probed with an anti-p85 antibody. (d) The Y173F mutation inhibits CD2/28-mediated activation of associated PI 3-kinase. Cells were either left unstimulated or were stimulated for 5 min with the CD2-specific monoclonal antibody TS2/18, and the CD2/28 receptor was immunoprecipitated from cell lysates. PI 3-kinase activity in cell lysates was measured as previously described [38] by in vitro phosphorylation of the PI 3-kinase substrate -PI -followed by thin layer chromatography (TLC) and visualization of the labeled PI product (PI 3-phosphate, PIP) by autoradiography. The fold increase in PI 3-kinase activity upon stimulation for each transfectant was determined by phosphorimager analysis of the TLC plate. A role for PI 3-kinase in CD28-mediated activation of β1 integrin function was tested by transiently expressing a dominant-negative p85 construct tagged with green fluorescent protein (GFP-∆p85; Figure 2a ). The GFP tag enabled us to use flow cytometry to quantitate the adhesion of the subpopulation of transiently transfected cells expressing GFP-∆p85, as well as the larger population of transfected cells in the same sample that did not express GFP-∆p85 ( Figure 2a ) [6] . CD2/28-induced adhesion of HL60 cells to fibronectin was inhibited in transiently transfected cells expressing the GFP-∆p85 construct (Figure 2b ). The inhibitory effects of GFP-∆p85 were not due to global inhibition of integrin function or cell adhesive capabilities, as integrin activation induced by PMA or direct β1 integrin stimulation was not inhibited by GFP-∆p85. Furthermore, expression of GFP itself did not inhibit adhesion induced by either CD2/28 stimulation, PMA stimulation or direct β1 integrin activation (Figure 2b ). This suggests that the inhibitory effect of the GFP-∆p85 construct on CD2/28-mediated activation of β1 integrins was due specifically to the expression of the dominant-negative p85 protein.
To determine the ability of GFP-∆p85 to associate with the CD28 cytoplasmic tail, HL60(CD2/28) cells were transiently transfected with GFP-∆p85 and sorted by flow cytometry to isolate cells expressing GFP-∆p85 (GFP-∆p85 + cells). The resulting population of cells expressed low, but uniform levels of GFP-∆p85 (mean channel fluorescence of 37). Stimulation of CD2/28 resulted in association of the 115 kDa GFP-∆p85 fusion protein with the CD2/28 chimera ( Figure 2c ). The relatively low level of GFP-∆p85 expression in the sorted cells allowed for some endogenous p85 also to associate with CD2/28 in this experiment.
We produced additional stable transfectants expressing CD2/28 chimeras where each of the four tyrosine residues in the CD28 cytoplasmic domain was mutated to phenylalanine. Each mutant chimera was expressed in HL60 cells at levels comparable to those for CD2/28 ( Figure 1a ). The only mutation that affected CD28-mediated activation of adhesion was the tyrosine to phenylalanine mutation at position 173 in the YMNM SH2-binding site of the CD28 cytoplasmic domain (CD2/28Y173F; Figure 1b ). This mutation also inhibited activation-induced association of p85 ( Figure 1c ) and the subsequent activation of PI 3-kinase associated with the CD28 cytoplasmic tail ( Figure 1d ). Thus, these results suggest a critical role for the YMNM SH2-binding motif in the CD28 cytoplasmic domain in CD28-mediated integrin activation.
Identification of a CD28 cytoplasmic domain mutation that blocks integrin activation but not coupling to PI 3-kinase
To further characterize the role of the YMNM SH2-binding motif in coupling CD28 to PI 3-kinase and integrin activation, the YMNM sequence found in the CD28 cytoplasmic tail was replaced with the sequence YVKM creating CD2/28YVKM. We chose this sequence because it is found in the cytoplasmic domain of the CD28-related receptor CTLA-4, which has been shown to be capable of associating with PI 3-kinase upon activation [30] . HL60 transfectants were obtained that expressed CD2/28YVKM on the cell surface at levels comparable to those for CD2/28 ( Figure 3a ). Like wild-type CD28, activation of CD2/28YVKM resulted in the recruitment of p85 and activation of PI 3-kinase coprecipitated with the receptor (Figure 3b ). However, activation of CD2/28YVKM failed to induce increased adhesion to fibronectin at any of the time points tested (Figure 3c ). This was not due to defects in β1 integrin expression in this transfectant, since β1 integrin expression levels did not differ from HL60(CD2/28) transfectants and untransfected HL60 cells (Figures 1a,3a) . Furthermore, β1 integrin function was not impaired in HL60(CD2/28YVKM) transfectants, since PMA stimulation and direct activation of β1 integrins with the TS2/16 monoclonal antibody induced increases in adhesion comparable to those seen with HL60(CD2/28) transfectants (Figure 3c ). Thus, these results suggest that recruitment of PI 3-kinase to the CD28 cytoplasmic tail and subsequent PI 3-kinase activation is not sufficient to activate integrins.
CD28 cytoplasmic domain mutations that block integrin activation also impair tyrosine phosphorylation of Cbl
Our results with the CD2/28YVKM chimeric receptor suggest the possibility that the CD28 cytoplasmic tail activates integrins via a mechanism independent of direct recruitment of PI 3-kinase to CD28. To investigate this hypothesis, we examined the ability of CD28 stimulation to induce association and activation of PI 3-kinase with known adaptor proteins. As Cbl has previously been identified as a substrate for tyrosine kinase activity stimulated by CD28 ligation [31] , we immunoprecipitated cell lysates with a Cbl-specific antibody and immunoblotted with an anti-phosphotyrosine monoclonal antibody. Figure 4a shows that CD2/28 cross-linking resulted in tyrosine phosphorylation of Cbl. Immunoblotting of the same anti-Cbl immunoprecipitates with a p85-specific antibody demonstrated that CD2/28 cross-linking resulted in association of the p85 subunit of PI 3-kinase with tyrosine phosphorylated Cbl (Figure 4a ). To determine if the induced association of p85 with Cbl resulted in increased Cbl-associated PI 3-kinase activity, we performed PI 3-kinase activity assays with anti-Cbl immunoprecipitates from HL60(CD2/28) cells. Figure 4b shows that stimulation of the CD2/28 chimeric receptor induced a rapid and transient increase in Cbl-associated PI 3-kinase activity. Thus, stimulation of the CD2/28 chimera results in tyrosine phosphorylation of Cbl, the coprecipitation of p85 with tyrosine-phosphorylated Cbl (Figure 4a ), and increased PI 3-kinase activity in anti-Cbl immunoprecipitates (Figure 4b ).
Sequential immunoprecipitation experiments were performed to determine if CD28 stimulation resulted in the recruitment of a Cbl-p85 complex to the CD28 cytoplasmic domain. Lysates from unstimulated and CD2/28-stimulated HL60(CD2/28) transfectants were first depleted of CD2/28 chimeric protein by three sequential immunoprecipitations with a CD2-specific monoclonal antibody, followed by immunoprecipitation with a Cbl-specific antibody. Figure 4c shows that Cbl was not detected in immunoprecipitates containing the CD2/28 chimera. In addition, Cbl was immunoprecipitated from lysates of unstimulated and CD2/28-stimulated cells that were extensively precleared of the CD2/28 chimera (Figure 4c ). Immunodepletion of CD2/28 from cell lysates also did not affect the amount of PI 3-kinase activity associated with Cbl (data not shown). Although Grb2 has been reported to associate with Cbl [20, 23, 24] and CD28 [10] , we were unable to detect the association of Grb2 with the CD28 cytoplasmic domain in our system (data not shown). These results suggest that CD2/28 stimulation does not result in the association of Cbl with the CD28 cytoplasmic domain and that the PI 3-kinase activity associated with Cbl following CD2/28 stimulation is distinct from the PI 3-kinase activity directly associated with the receptor itself. Thus, activation by CD28 of two distinct pools of PI 3-kinase may provide additional levels of complexity and specificity in the regulation of downstream responses that are dependent on PI 3-kinase activation. As several isoforms of PI 3-kinase have been identified [32] , it is also possible that activation of different PI 3-kinase isoforms may be a reflection of these distinct pools of PI 3-kinase.
We next examined the effect of various CD28 cytoplasmic domain mutations on CD28-mediated tyrosine phosphorylation of Cbl and association and activation of PI 3-kinase with Cbl. Anti-phosphotyrosine immunoblotting demonstrated that mutations of the tyrosine residues at positions 188, 191 and 200 partially reduced the ability of the CD2/28 chimera to induce tyrosine phosphorylation of Cbl (Figure 4a ). However, this reduction in tyrosine phosphorylation of Cbl by the Y188F, Y191F and Y200F mutations had little effect on the amount of p85 detected in anti-Cbl immunoprecipitates upon CD2/28 cross-linking. In contrast, the Y173F substitution resulted in dramatically reduced tyrosine phosphorylation of Cbl and p85 recruitment upon chimera cross-linking (Figure 4a ). These results demonstrate a role for tyrosine 173 in CD28-mediated tyrosine phosphorylation of Cbl and recruitment of p85 to Cbl, perhaps by regulating the activation of a tyrosine kinase involved in Cbl phosphorylation. Alternatively, activation of PI 3-kinase by the CD28 cytoplasmic domain itself may play a role in activating a downstream kinase, as the lipid products of PI 3-kinase are capable of directly interacting with kinases containing SH2 and pleckstrin homology domains [33, 34] .
The YVKM substitution also significantly inhibited tyrosine phosphorylation of Cbl (Figure 4d) , as well as recruitment and activation of PI 3-kinase in anti-Cbl immunoprecipitates (Figure 4b,d) . Thus, receptors that were not able to mediate integrin activation (CD2/28Y173F and CD2/28YVKM) exhibited dramatically reduced ability to induce tyrosine phosphorylation of Cbl and activate Cbl-associated PI 3-kinase.
Inhibition of CD28-mediated activation of b1-integrinmediated adhesion by a Cbl mutant
To examine the role of Cbl in integrin activation, we transiently expressed fusion constructs encoding GFP-tagged CD28-mediated tyrosine phosphorylation of Cbl, and activation of Cbl-associated PI 3-kinase. (a) The Y173F mutation inhibits CD2/28-mediated tyrosine phosphorylation of Cbl and coprecipitation of p85 with Cbl. Cells were either left unstimulated (-) or were stimulated for 5 or 10 min with the CD2-specific monoclonal antibody TS2/18, and Cbl was immunoprecipitated from cell lysates and subjected to SDS-PAGE. Western blots were sequentially probed with the antiphosphotyrosine monoclonal antibody 4G10 (anti-PTyr), an anti-Cbl antibody, and an antip85 antibody. (b) Cbl immunoprecipitates from unstimulated and stimulated HL60(CD2/28) and HL60(CD2/28Y173F) cells were analyzed for PI 3-kinase activity as previously described [38] . The fold increase in PI 3-kinase activity in lysates from unstimulated cells (-), and lysates from cells stimulated by CD2/28 cross-linking for 1 min, 5 min, 10 min and 20 min was calculated by assigning the density volume of the unstimulated sample a value of one. Results shown are average fold increases in PI 3-kinase activity from three independent experiments ± the standard deviation. (c) Cbl does not coprecipitate with the CD2/28 receptor. HL60(CD2/28) cells were either left unstimulated or were stimulated by CD2/28 cross-linking for 5 min and then lysed. Lysates were first depleted of CD2/28 chimeric protein by three sequential immunoprecipitations with a CD2-specific monoclonal antibody (steps 1-3) followed by immunoprecipitation with anti-Cbl polyclonal antibody (step 4). Samples from each step were subjected to SDS-PAGE and western blots were sequentially probed with an anti-CD2 monoclonal antibody and an anti-Cbl antibody. The band labeled Ig represents the immunoprecipitating antibody that is detected by the western blotting procedure. wild-type Cbl and GFP-tagged 70Z/3-Cbl, a mutant form of Cbl that contains a 17 amino acid deletion in the zinc ring finger region of the Cbl protein [35, 36] , in HL60(CD2/28) cells. The 70Z/3-Cbl mutant exhibits hyperphosphorylation but reduced association with p85 upon CD28 stimulation. Expression of the GFP-Cbl proteins was obtained in 20-30% of the transfected cell population (Figure 5a ) and did not affect levels of β1 integrin expression (data not shown). Anti-GFP immunoprecipitates were analyzed by western blotting to determine the effects of CD2/28 stimulation on tyrosine phosphorylation of GFP-Cbl and association of p85 with GFP-Cbl. As seen with endogenous Cbl, CD2/28 stimulation resulted in increased tyrosine phosphorylation of Cbl and recruitment of p85 (Figure 5b ). The 70Z/3-Cbl protein exhibited significant levels of basal tyrosine phosphorylation in unstimulated HL60(CD2/28) cells. Furthermore, CD2/28 stimulation resulted in much stronger tyrosine phosphorylation of 70Z/3-Cbl than wildtype Cbl (Figure 5b ). However, this was not accompanied by increased association of p85 with 70Z/3-Cbl. In fact, when normalized to the amount of Cbl immunoprecipitated in each sample, there was reduced association of p85 with 70Z/3-Cbl compared with wild-type Cbl in CD2/28-stimulated cells. Similarly, even though 70Z/3-Cbl was hyperphosphorylated in unstimulated cells, there was little detectable coprecipitating p85. Thus, these results suggest that the deletion in 70Z/3-Cbl impairs the ability of p85 to associate with Cbl following CD2/28 stimulation.
In adhesion assays, expression of GFP-Cbl had no effect on the adhesion of unstimulated cells or cells stimulated by CD2/28 activation, PMA or direct activation of β1 integrins (Figure 5c ). In contrast, expression of GFP-70Z/3-Cbl specifically inhibited adhesion induced by stimulation of the CD2/28 receptor. Gating on transiently transfected cells expressing varying levels of GFP-70Z/3-Cbl, shown in Figure 5a , also revealed a dose-dependent inhibitory effect of 70Z/3-Cbl on CD2/28-mediated adhesion in the various populations (Figure 5c ). This therefore suggests that 70Z/3-Cbl has a dominant-negative effect on integrin activation induced by the CD28 cytoplasmic domain.
The inhibitory effect of GFP-70Z/3-Cbl on integrin function was specific for signaling induced by CD2/28, as
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Figure 5
Inhibition of CD28-mediated activation of β1 integrins by 70Z/3-Cbl. GFP-Cbl GFP-70Z/3-Cbl expression of GFP-70Z/3-Cbl did not affect adhesion induced by PMA or the activating β1-integrin-specific monoclonal antibody TS2/16 ( Figure 5c ). In addition, stimulation of the CD64 (FcγRI) receptor, which activates PI 3-kinase [37] and is expressed at moderate levels on HL60 cells (data not shown), resulted in increased adhesion of HL60 cells to fibronectin (Figures 2b,5d ). Whereas CD64-mediated activation of adhesion was also inhibited by GFP-∆p85 (Figure 2b ) and by the PI 3-kinase inhibitor wortmannin (data not shown), it was unaffected by expression of 70Z/3-Cbl (Figure 5d ). Thus, even though CD28 and CD64 both appear to use PI 3-kinase to activate adhesion, there is a differential role for Cbl in regulating adhesion by these two receptors. This suggests that the role of Cbl in regulation of integrin-mediated adhesion is dependent on the nature of the activating stimulus.
We have previously proposed a central role for PI 3-kinase in the activation of integrin-mediated adhesion induced by the CD28 antigen, as well as other receptors that are capable of activating integrin function [17] . The ability of a dominant-negative form of the p85 subunit of PI 3-kinase to specifically inhibit CD28-mediated activation of β1-integrin-mediated cell adhesion is consistent with this hypothesis. As CD28 associates with and activates PI 3-kinase via binding of the p85 subunit to the tyrosinephosphorylated YMNM SH2-binding motif [9] [10] [11] , we reasoned that mutations in the CD28 cytoplasmic domain that inhibit the direct recruitment of PI 3-kinase to CD28 should also block CD28-mediated activation of β1 integrins. The Y173F mutation in the SH2-binding motif inhibited CD28-induced association and recruitment of PI 3-kinase to CD28, and also blocked CD28-induced activation of integrin-mediated adhesion. In contrast, mutation of the remaining three tyrosine residues in the CD28 cytoplasmic domain failed to inhibit either PI 3-kinase recruitment to CD28 or integrin activation.
When we substituted the YMNM-binding motif with the YVKM sequence found in the CTLA-4 antigen, however, we observed that activation of PI 3-kinase directly coprecipitated with the CD2/28 chimera was uncoupled from effects on integrin activation. Thus, the CD2/28YVKM chimera retained an ability to associate with and activate PI 3-kinase, but failed to activate integrin-mediated adhesion. This result suggested that direct coupling of PI 3-kinase to the CD28 cytoplasmic domain was not sufficient to engage PI-3-kinase-dependent pathways of integrin activation. We propose instead that Cbl may be involved as an intracellular adaptor that is specifically involved in coupling CD28 to a pool of PI 3-kinase that can be distinguished biochemically and functionally from the PI 3-kinase that is coprecipitated with the CD28 cytoplasmic domain itself. Several lines of evidence support this model. First, CD28 ligation has been shown to result in tyrosine phosphorylation of Cbl [31] . Second, tyrosine phosphorylation of Cbl has been shown in many cell systems to result in the association of p85 with Cbl [20, 23, 26] . Third, the two CD28 cytoplasmic domain mutations that block CD28-induced activation of integrinmediated adhesion, namely Y173F and YVKM, also inhibit CD28-mediated association of p85 with Cbl. Finally, CD28-mediated activation of integrin-mediated adhesion can be specifically blocked by 70Z/3-Cbl, a mutant form of Cbl that exhibits hyperphosphorylation but reduced association with p85 upon CD28 stimulation.
Our results suggest a previously unappreciated function for the Cbl adaptor protein -regulation of agonistinduced cell adhesion. It is possible that other receptors that activate integrins may also achieve similar effects via tyrosine phosphorylation of Cbl and recruitment or activation of PI 3-kinase [6, 17, 38, 39] . Other studies with Cbl have analyzed its role in regulating Ras-dependent signaling [40] . However, a consistent picture of how Cbl regulates the Ras pathway has not emerged. Although antisense-mediated inhibition of Cbl did not affect Ras signaling initiated by the epidermal growth factor receptor [41] , expression of 70Z/3-Cbl enhanced Ras-dependent activation of a reporter gene responsive to nuclear factor of activated T cells (NFAT) [28] . Hyperphosphorylation of Cbl, resulting in activation of the GTPase Rap1, may be involved in the maintenance of clonal anergy in T cells via negative regulation of Ras-dependent signaling [42] . Cbl has also been implicated in the negative regulation of the tyrosine kinase Syk [21] . The 70Z/3-Cbl mutant that we used in this study has also been shown to have transforming ability [35, 36] . As changes in integrin-mediated adhesion are a hallmark of cellular transformation, our studies demonstrating an inhibitory effect of 70Z/3-Cbl on integrin activation may also have relevance to the transforming function of this Cbl mutant.
Conclusions
We describe a novel role for the Cbl adaptor protein in CD28-mediated regulation of β1-integrin-mediated cell adhesion. CD28 stimulation results in the activation of two distinct pools of PI 3-kinase, one associated with the CD28 cytoplasmic domain and one associated with tyrosine-phosphorylated Cbl. Although activation of both pools of PI 3-kinase is dependent on the integrity of the SH2-binding motif in the CD28 cytoplasmic domain, the ability of a mutant form of Cbl to specifically block CD28-mediated integrin activation suggests a role for Cbl in the regulation of cell adhesion. These studies identify Cbl as a new intracellular target for modulating integrin-mediated adhesion.
Materials and methods

Cell lines
The HL60 cell line was maintained in RPMI 1640 medium supplemented with 5% FCS (Atlanta Biologicals), L-glutamine, and penicillin/streptomycin. During G418 selection after electroporation, the concentration of FCS was increased to 10%.
Flow cytometry and cell sorting
Single-color flow cytometric analysis was performed using the CD2-specific monoclonal antibody TS2/18 (ATCC), β1-integrin-specific monoclonal antibody TS2/16 (ATCC), α4-integrin-specific monoclonal antibody NIH49d-1 (kind gift of S. Shaw), and α5-specific monoclonal antibody P1D6 (GIBCO/BRL) and FITC-conjugated goat anti-mouse IgG as previously described [13] . Data was acquired on a Becton Dickinson FACScan and analyzed using Cellquest software. HL60(CD2/28) cells transiently expressing the GFP-∆p85 construct were sorted in the University of Minnesota Cancer Center Flow Cytometry Core Facility with a FACSVantage using the enrich mode.
DNA constructs
All CD2/28 chimeric receptor constructs were made by RT-PCR gene synthesis as previously described [13] using the pMH-NeoH.CD2 vector [38] . All plasmids were sequenced to confirm the fidelity of the amplification reaction. The GFP-∆p85 construct has been described previously [6] . The GFP-Cbl constructs were produced by subcloning a 2.7 kb fragment containing wild-type Cbl or 70Z/3-Cbl (provided by W. Langdon) in-frame into the SacII-SalI sites in the pEGFP-C2 carboxy-terminal protein fusion vector (Clontech).
DNA-mediated gene transfer
Transfections were performed by electroporation as previously described [38] . Stable G418-resistant cells were isolated by selection in 1 mg/ml G418 and CD2-positive transfectants identified by flow cytometry. A minimum of two or three subclones of each transfectant expressing the same chimeric receptor were tested in subsequent experiments. Expression of the correct CD2/28 receptor was verified by western blotting and DNA sequencing. For transient transfections, HL60(CD2/28) cells were transfected by electroporation as previously described [6] and harvested for analysis in adhesion assays or by western blotting 16-24 h after transfection.
Adhesion assays
Adhesion of HL60 transfectants to purified fibronectin was performed using calcein-AM or 51 Cr labeling as previously described [13] . For transient transfectants expressing GFP fusion proteins, adhesion was quantified by collection of adherent cells and analysis by flow cytometry as previously described [6] . Stimulation conditions were 10 ng/ml PMA, cross-linking of CD2/28 with the CD2-specific monoclonal antibody TS2/18 (ATCC) and goat anti-mouse IgG, cross-linking of CD64 with the CD64-specific monoclonal antibody 32.2 (ATCC) and goat anti-mouse IgG, or direct activation of β1 integrins with the monoclonal antibody TS2/16 (ATCC).
Western blotting
Immunoprecipitations were performed as previously described [38] using either the anti-CD2 monoclonal antibody 35.1 (ATCC), an antiCbl polyclonal antibody (Santa Cruz Biotechnology) or an anti-GFP polyclonal antibody (Clontech). Immunoprecipitated proteins were separated on 7.5% SDS-polyacrylamide gels, transferred to Immobilon-P membranes (Millipore), and immunoblotted with the indicated antibodies followed by detection with enhanced chemiluminescence (Pierce).
Sequential immunodepletion experiments were performed as previously described [43] .
PI 3-kinase activity assays
PI 3-kinase activity in anti-CD2 or anti-Cbl immunoprecipitates was assessed as previously described [38] . Radioactive lipid product was visualized by autoradiography and quantified using a phosphorimager (Molecular Dynamics).
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